Immunovaccine Inc., a clinical stage vaccine and immunotherapy company, today announced that it will be presenting at the 8th annual LD Micro Main Event on Thursday, December 3, at 10:00 am PST, 1:00 pm EST. Albert Scardino, chairman of Immunovaccine will be giving the presentation and meeting with investors. The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 210 companies in the small/micro-cap space.

About Immunovaccine 
Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is expected to enter additional Phase 2 clinical studies in ovarian cancer and glioblastoma (brain cancer). The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax. Connect at www.imvaccine.com.

About LD Micro 
LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Invitational in June. It is a non-registered investment advisor. For more information, please contact 408.457.1042 or visit www.ldmicro.com.

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

For more information, contact:

Marc Mansour 
CEO
Immunovaccine Inc.
T 902.492.1819 
mmansour@imvaccine.com 

Halifax, NS, November 25, 2015